Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F

Oncogene

Volumn 30, Issue 8, 2011, Pages 990-1001

  Boissinot, M ^a,b   Cleyrat, C ^a   Vilaine, M ^a   Jacques, Y ^a   Corre, I ^a   Hermouet, S ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

hepatocyte growth factor (HGF); inflammation; interleukin 11 (IL 11); interleukin 6 (IL 6); JAK2V617F; Polycythemia vera

Indexed keywords

CYTOKINE ANTIBODY; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; LEPTIN; MACROPHAGE CHEMOTACTIC FACTOR; SCATTER FACTOR; STEM CELL FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BONE MARROW EXAMINATION; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROBLAST; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL PROLIFERATION; CLONE CELLS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROBLASTS; FEMALE; GENE EXPRESSION PROFILING; HEPATOCYTE GROWTH FACTOR; HUMANS; INFLAMMATION; INTERLEUKIN-11; JANUS KINASE 2; MALE; MUTATION; POLYCYTHEMIA VERA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 79952006897     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.479     Document Type: Article

References (55)

1. Aman MJ, Bug G, Aulitzky WE, Huber C, Peschel C. (1996). Inhibition of interleukin-11 by interferon-alpha in human bone marrow stromal cells. Exp Hematol 24: 863-867. (Pubitemid 26255100)
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Cancer Genome Project et al. (2005). Acquired mutation of the tyrosine kinase JAK-2 in human myeloproliferative disorders. Lancet 365: 1054-1061. (Pubitemid 40386783)
3. Bernet A, Mehlen P. (2007). Dependence receptors: when apoptosis controls tumor progression. Bull Cancer 94: E12-E17.
4. Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau J-L et al. (2010). JAK2 mutation and disease phenotype: A double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia 24: 1069-1073.
5. Comoglio PM, Giordano S, Trusolino L. (2008). Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516. (Pubitemid 351767118)
6. Coppo P, Dusanter-Fourt I, Vainchenker W, Turhan AG. (2009). BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cell Signal 21: 52-60.
7. Corre-Buscail I, Pineau D, Boissinot M, Hermouet S. (2005). Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukins 11 and 8. Exp Hematol 33: 1299-1308. (Pubitemid 41540518)
8. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM et al. (2003). The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17: 764-774. (Pubitemid 36519374)
9. Dobo I, Donnard M, Girodon F, Mossuz P, Boiret N, Boukhari R et al. (2004). Standardization and comparison of endogenous erythroid colony assay performed with bone marrow or blood progenitors for the diagnosis of polycythaemia vera. Hematol J 5: 161-167. (Pubitemid 38519266)
10. Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M et al. (2007). NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 109: 3042-3049. (Pubitemid 46482105)
11. Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR et al. (2010). Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn' disease in a New Zealand population. Mutat Res 690: 108-115.
12. Geissler K, Ohler L, Fodinger M, Kabrna E, Kollars M, Skoupy S et al. (1998). Interleukin-10 inhibits erythropoietin-independent growth of erythroid bursts in patients with polycythemia vera. Blood 92: 1967-1972. (Pubitemid 28446686)
13. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Dos Santos F et al. (2008). Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxurea therapy. Haematologica 93: 1723-1727.
14. Giuliani N, Colla S, Morandi F, Rizzoli V. (2004). The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica 89: 1118-1123. (Pubitemid 39295483)
15. Hermouet S, Godard A, Pineau D, Corre I, Raher S, Lippert E et al. (2002). Abnormal production of interleukin (IL)-11 and IL-8 in polycythemia vera. Cytokine 20: 178-183. (Pubitemid 37163469)
16. Hitoshi Y, Lin N, Payan DG, Markovtsov V. (2010). The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol 91: 189-200.
17. Ho CL, Lasho TL, Butterfield JH, Tefferi A. (2007). Global cytokine analysis in myeloproliferative disorders. Leuk Res 31: 1389-1392. (Pubitemid 47212423)
18. Ishii T, Zhao Y, Shi J, Sozer S, Hoffman R, Xu M. (2007). T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation. Leukemia 21: 2433-2441. (Pubitemid 350148885)
19. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148. (Pubitemid 40663494)
20. Jenkins BJ, Roberts AW, Najdovska M, Grail D, Ernst M. (2005). The threshold of gp130-dependent STAT3 signalling is critical for normal regulation of hematopoiesis. Blood 105: 3512-3520. (Pubitemid 40628193)
21. Jenkins BJ, Roberts AW, Greenhill CJ, Najdovska M, Lundgren-May T, Robb L et al. (2007). Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 109: 2380-2388. (Pubitemid 46425878)
22. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL et al. (2009). JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41: 446-449.
23. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S et al. (2006). High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108: 2037-2040. (Pubitemid 44395018)
24. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL et al. (2009). A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41: 455-459.
25. Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. (2008). Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci 99: 1341-1347. (Pubitemid 351761722)
26. Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S et al. (2007). Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67: 8615-8623. (Pubitemid 47437437)
27. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. (2005). A gain-of-function mutation of JAK-2 in myeloproliferative disorders. New Engl J Med 352: 1779-1790. (Pubitemid 40570926)
28. Kralovics R. (2008). Genetic complexity of myeloproliferative neoplasms. Leukemia 22: 1841-1848.
29. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. (2006). JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652-1660. (Pubitemid 44316134)
30. Lambert JR, Everington T, Linch DC, Gale RE. (2009). In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 114: 3018-3023.
31. Le Bousse-Kerdilé s MC, Martyré MC. (1999). Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 78: 437-444 . Review.
32. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. (2006). The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108: 1865-1867. (Pubitemid 44394995)
33. Lippert E, Girodon F, Hammond E, Reading NS, Jelinek J, Badbaran A et al. (2009). Concordance of assays designed for the quantitation of JAK2V617F (1849G>T): a multi-centre study. Haematologica 94: 38-45.
34. Matsuda-Hashii Y, Takai K, Ohta H, Fujisaki H, Tokimasa S, Osugi Y et al. (2004). Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. Exp Hematol 32: 955-961. (Pubitemid 39410710)
35. Musolino C, Calabro L, Bellomo G, Martello F, Loteta B, Pezzano C et al. (2002). Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 69: 159-163. (Pubitemid 34177468)
36. Najfeld V, Cozza A, Berkofsy-Fessler W, Prchal J, Scalise A. (2007). Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 35: 1668-7166.
37. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S et al. (2007). Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35: 32-38.
38. Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I et al. (2009). A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41: 450-454.
39. Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J et al. (2005). Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. British J Haematol 130: 709-715. (Pubitemid 43906643)
40. Quesniaux VF, Clark SC, Turner K, Fagg B. (1992). Interleukin-11 stimulates multiple phases of erythropoiesis in vitro. Blood 80: 1218-1223.
41. Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, Cai H et al. (2002). Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122: 1020-1034. (Pubitemid 34267285)
42. Sattler M, Salgia R. (2007). c-MET and hepatocyte growth factor: potential new targets in cancer therapy. Curr Oncol Rep 9: 102-108. (Pubitemid 46332381)
43. Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F et al. (2009). Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the pre-disposing mutations for JAK2-V617F. Blood 113: 2022-2027.
44. Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ. (1999). Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 13: 1307-1315. (Pubitemid 29429755)
45. Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW et al. (2004). RNA interference reveals that ligand-independent MET activity is required for tumor cell signalling and survival. Cancer Res 64: 7962-7970. (Pubitemid 39446930)
46. Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V. (2007). Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res 67: 9913-9920. (Pubitemid 47621240)
47. Tacchini L, Dansi P, Matteucci E, Desiderio MA. (2001). Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 22: 1363-1371. (Pubitemid 32898691)
48. Tefferi A. (2010). JAK inhibitors in myeloproliferative neoplasms. The Hematologist 7: 5 . Review.
49. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. (2008). Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-3940.
50. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. (1993). Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82: 3712-3720. (Pubitemid 24006055)
51. Vardiman JW, Harris NL, Brunning RD. (2002). The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302.
52. Verstovsek S. (2010). Therapeutic potential of janus-activated Kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res 16: 1988-1996.
53. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. (2006). Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274-4281. (Pubitemid 43801351)
54. Wickenhauser C, Thiele J, Lorenzen J, Schmitz B, Frimpong S, Schramm K et al. (1999). Polycythemia vera megakaryocytes but not megakaryocytes from normal controls and patients with smoker's polycythemia spontaneously express IL-6 and IL-6R and secrete IL-6. Leukemia 13: 327-334. (Pubitemid 29108070)
55. Zdzisinska B, Bojarska-Junak A, Dmoszynska A, Kandefer-Szerszen M. (2008). Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp 56: 207-221.